STOCK TITAN

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
I-Mab, a global biotechnology company, will be participating in two conferences in November 2023: the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. The company's CEO, Dr. Raj Kannan, and CMO, Dr. John Hayslip, will be presenting at both conferences. The conferences will provide opportunities for one-on-one and small group meetings with management. The webcast of the Jefferies conference will be available on I-Mab's IR website.
Positive
  • None.
Negative
  • None.

ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. Details of the conferences and management presentation are as follows:

Jefferies London Healthcare Conference (In Person)

Presentation Time

Tuesday, November 14th at 10:30 a.m. GMT (5:30 a.m. EST)

Presenters

Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO

Webcast link

https://wsw.com/webcast/jeff287/imab/1828028
The webcast will also be available under "Event Calendar" on I-Mab's IR website
at 
http://ir.i-mabbiopharma.com/

Meetings

One-on-one and small group meetings: Nov 14 – 16, 2023

Management
Participants

Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO
Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Jefferies representative.

Piper Sandler 35th Annual Healthcare Conference (In Person)

Presentation Time

Thursday, November 30th at 8:30 a.m. EST

Presenters

Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO

Meetings

One-on-one and small group meetings: Nov 28 – 30, 2023                                   

Management
Participants

Mr. Raj Kannan, CEO
Dr. John Hayslip, CMO
Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Piper Sandler representative.

About I-Mab

I-Mab (Nasdaq: IMAB) is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedInX, formerly known as Twitter, and WeChat.

I-Mab Contacts

Investors

Media

Tyler Ehler

Gigi Feng

Senior Director, Investor Relations

Chief Communications Officer

IR@i-mabbiopharma.com

PR@i-mabbiopharma.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-participation-at-jefferies-and-piper-conferences-in-november-301978319.html

SOURCE I-Mab

I-Mab is participating in the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference.

Dr. Raj Kannan, CEO, and Dr. John Hayslip, CMO, will be presenting at both conferences.

Yes, there will be one-on-one and small group meetings with management at both conferences.

The webcast of the Jefferies conference will be available on I-Mab's IR website.

For more information, please contact your Jefferies representative for the Jefferies conference, and your Piper Sandler representative for the Piper Sandler conference.
I-Mab

NASDAQ:IMAB

IMAB Rankings

IMAB Latest News

IMAB Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing

About IMAB

i-mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. it is developing felzartamab (tj202), a cd38 antibody that is in phase iii clinical trials to treat multiple myeloma and autoimmune diseases; eftansomatropin (tj101), a long-acting human growth hormone that has completed phase ii clinical trials to treat pediatric growth hormone deficiency; and olamkicept (tj301), a il-6 blocker, which is in phase ii clinical trials for the treatment of ulcerative colitis and autoimmune diseases. the company's product candidates also include enoblituzumab, a humanized b7-h3 antibody that has completed phase i clinical trials to treat head and neck cancer and other oncology diseases; efineptakin (tj107), a long-acting recombinant human il-7, which is in phase 2 clinical trials to treat glioblastoma multiforme (gbm